Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

PCSK9 List Price Discounts Of 67% To 85% Suggested By ICER Analysis

Executive Summary

Methods and conclusions for group’s report on the value and optimal pricing for Repatha and Praluent draw criticism from drug industry stakeholders, some policy experts. Approach includes cost-effectiveness review, novel US budget impact analysis.


Related Content

Value Vs. Values: ICER’s Review Of Opioid Abuse-Deterrent Formulations
PCSK9 Inhibitors' First Birthday Brings Sluggish Sales And More Bad Press
ICER Eyes QALY Ratios, Budget Impacts In Methods Review


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst